about
SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1Transcriptional activation of the adenoviral genome is mediated by capsid protein VIUbiquitin-independent degradation of proteins by the proteasomeRegulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes.E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation.Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses.Sumoylation inhibits alpha-synuclein aggregation and toxicity.Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?SUMO: regulating the regulator.JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosisSUMO2/3 modification of cyclin E contributes to the control of replication origin firing.SUMO under stress.Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein.The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression.Cellular and viral Fos proteins are degraded by different proteolytic systems.CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion.SUMOylation regulates the transcriptional activity of JunB in T lymphocytes.The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.A fluorescence resonance energy transfer-based assay to study SUMO modification in solution.Production and Purification of Recombinant SUMOylated Proteins Using Engineered Bacteria.Detection of Protein-Protein Interactions and Posttranslational Modifications Using the Proximity Ligation Assay: Application to the Study of the SUMO Pathway.DUOX2-mediated production of reactive oxygen species induces epithelial mesenchymal transition in 5-fluorouracil resistant human colon cancer cells.NF-κB activation upon interaction of HIV-1 envelope glycoproteins with cell surface CD4 involves IκB kinasesSUMO Safeguards Somatic and Pluripotent Cell Identities by Enforcing Distinct Chromatin States[Proteasomal degradation: from addressing of substrates to therapeutical perspectives]Targeting the SUMO Pathway Primes All-trans Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid LeukemiasParticulate matter-induced senescence of skin keratinocytes involves oxidative stress-dependent epigenetic modificationsUbiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapiesTargeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid LeukemiaThe SUMO Pathway in Hematomalignancies and Their Response to Therapies
P50
Q24676460-3407ED13-E3BF-4440-9431-88C5E3032A70Q27347199-82B231C6-4304-437B-846B-66CB671D03CBQ28284043-4964D684-9349-43EE-A034-286FD347D936Q34491014-B83F0F41-DEF1-4618-9E13-96FBFF68F838Q34582315-45395C33-E422-42FB-A527-92AEF5A38994Q34816261-115C8CF6-3DE4-4A9F-8E9B-76815B95D106Q35102441-57349ADE-2EDE-471A-BA6C-68722CCDF829Q36076256-DA35368D-7226-440F-9AB6-6A77B7FD48AFQ36522036-F0F0613E-7543-4AE1-B0C0-F664E5D533D2Q36710812-C4F54B21-FF62-4DBC-9770-8431AC3D74ABQ36906799-C9794426-F66D-4357-BB09-611D47030BBCQ37269500-7ACBD635-237E-4BF3-9BB5-7A9A5CF53776Q38708964-2E75A6D0-B211-4AE0-925F-C2AA6344F5F4Q39693837-3348F14D-AAFB-436A-9620-396B032443D7Q42804279-07648E9D-D2EA-478D-A555-61B9DDF99140Q43583419-55A1C436-59AB-4E6E-9FF9-B10E8C156248Q44220432-81B213B9-F4C9-4E02-9342-ECAA5A778006Q46634753-60E2CE98-0439-48C8-93F3-ED8380B7782EQ46882329-2DBB8B27-CFA0-4CA1-BDF9-251685F5D12DQ50748371-35A63F20-825E-4B90-BECA-C6C8F1F01938Q51163574-37C1F323-013F-44E2-BBD1-E2284D0CE478Q51524362-01A0E401-E3E3-4CB8-985B-B29B792702A0Q53689438-CC95CA76-E193-415A-AAB9-B6995A24ED10Q56422832-AA80E1C6-6F88-4AE1-94C1-9295AB69B96DQ58547318-631135F2-24D0-48AD-BBF6-8E80E8C209AAQ81362013-A79FC40B-5B5C-44D7-9FC6-2B1906CB9EC5Q87900835-D2DF44D5-F0A5-43AC-A7B2-7064B51FA673Q90261560-B5092BA2-6A3A-4A82-97A3-C18B3C502185Q92024500-8E8D89E2-5996-4A9E-9D2D-C830483435BBQ92263915-AE069AB7-19DD-4531-95D6-087596C8113DQ92570284-4516164F-42BE-407A-8D68-0926528DCC59
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guillaume Bossis
@ast
Guillaume Bossis
@en
Guillaume Bossis
@es
Guillaume Bossis
@nl
type
label
Guillaume Bossis
@ast
Guillaume Bossis
@en
Guillaume Bossis
@es
Guillaume Bossis
@nl
prefLabel
Guillaume Bossis
@ast
Guillaume Bossis
@en
Guillaume Bossis
@es
Guillaume Bossis
@nl
P106
P31
P496
0000-0002-3349-8250